Truly Extraordinary Drill Core Fuels Surge in Shares of This Junior Miner
It's not every day that a press release features a seasoned mining executive declaring, "In my entire career, I've never seen drill core like this—it's truly extraordinary." But that's exactly what happened today, as a junior mining company released an update on its ongoing drill program. Unsurprisingly, the announcement sparked investor excitement, sending the company's shares sharply higher at last check.
As mentioned, shares of Giant Mining Corp. (CSE: BFG) (OTC: BFGFF) are surging following news that drilling of Hole MHB-34 has surpassed 1,850 feet (563.88 meters). MHB-34 is the third of five planned holes in the company's 2025 diamond core drilling program at the Majuba Hill Porphyry Copper-Silver-Gold Deposit in Pershing County, Nevada.
The primary objective of the program is to expand known copper mineralization at Majuba Hill and move the project toward a new Mineral Resource Estimate.
'The strong presence of cuprite, native copper, and chalcopyrite in MHB-34 suggests we may be approaching the primary copper sulfide zone. We look forward to receiving the assays,' said Larry Segerstrom, member of Giant Mining's Board of Directors.
CEO David Greenway added: 'In my entire career, I've never seen drill core like this—it's truly extraordinary. With visible native copper extending beyond 1,600 feet, we've exceeded our initial expectations. Majuba Hill is emerging as a world-class copper, silver, and gold discovery—strategically positioned to support America's clean energy future and mineral independence. Nevada's excellent infrastructure and mining-friendly environment further enhance the project's value.'
The Majuba Hill Project is located in a mining-friendly jurisdiction and benefits from existing infrastructure, including well-maintained access roads, proximity to power supply, transportation routes (highway and rail), and potential sites for processing, waste management, and administration.
Shares of BFG are currently up 51.22% at $0.31 while U.S. listed shares (BFGFF) tack on a still impressive 35.45% on the news in late-morning trading.
Copyright © 2025 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
View more of this article on AllPennyStocks.com.
About AllPennyStocks.com Media, Inc.:
Founded in 1999, AllPennyStocks.com is one of North America's leading platforms for micro-cap insights.
Catering to both Canadian and U.S. markets, we provide a wealth of resources and expert content designed for everyone—from beginner investors to seasoned traders.
AllPennyStocks.com is rapidly gaining recognition as a leading authority in the micro-cap space, with our insightful content prominently featured across numerous top-tier financial platforms, reaching a broad audience of investors and industry professionals.
Want to showcase your company's story to a powerful network of investors? We can help you elevate your message and make a lasting impact. Contact us today.
Contact:
AllPennyStocks.com Media, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Calgary Herald
24 minutes ago
- Calgary Herald
Oxford Properties takes over seven office towers in Calgary and Vancouver business districts
Article content Oxford Properties, a Canadian investor in real estate and property management, has bought out seven downtown office towers in Calgary and Vancouver's business districts. Article content In a news release shared Tuesday, the Toronto-based company announced that it had bought out Canadian Pension Plan Investment Board's 50 per cent interest in the office properties for $730 million, leaving it with full ownership of the $1.5-billion portfolio. Article content Article content In Calgary, that includes the 25-storey Eau Claire Tower (611,000 sq. ft), Centennial Place (1.3 million sq. ft), 400 Third (820,000 sq. ft) and The Stack (558,000 sq. ft). In Vancouver, the company would own the Guinness Tower (262,000 sq. ft), Marine building (177,000 sq. ft) and the MNP Tower (277,000 sq. ft), amounting to a four million square foot portfolio. Article content Article content Five of the seven properties were built after 2010, with only 400 Third and Centennial Place built in 1988 and 2010, respectively. Article content The move is a reversal of the company's longtime previous practices to dispose of office assets. Article content 'Oxford has been a net seller of office for over a decade to achieve portfolio diversification. We believe now is an opportune time to rotate capital back into this asset class, and this portfolio ticks all the right boxes,' said Tyler Seaman, the company's executive vice-president. Article content 'As the asset and property manager of this portfolio, this transaction represents a compelling opportunity for us to further invest in markets that we not only understand intimately, but in buildings where our teams have built great relationships with our customers and where we consistently use this advantage to outperform the market.' Article content
Vancouver Sun
an hour ago
- Vancouver Sun
NDP on TMX: We didn't want it. They built it. So let's use its full potential
VICTORIA — The B.C. NDP government responded with mostly discouraging words this week to growing national speculation about a new pipeline to transport the country's oil to the West Coast. Prime Minister Mark Carney explored the idea of 'an oil pipeline to tidewater' with industry executives in Calgary on Sunday and with provincial and territorial leaders in Saskatoon on Monday. Ontario Premier Doug Ford described the pipeline as 'absolutely critical' to weaning Canada off excessive dependence on the U.S. market. Stay on top of the latest real estate news and home design trends. By signing up you consent to receive the above newsletter from Postmedia Network Inc. A welcome email is on its way. If you don't see it, please check your junk folder. The next issue of Westcoast Homes will soon be in your inbox. Please try again Interested in more newsletters? Browse here. Alberta Premier Danielle Smith spoke of a 'grand bargain' to deliver a 'million-barrel-a-day pipeline to the northwest B.C. coast' and '$20 billion a year in revenues' to government coffers. Then there were the comments of B.C. deputy premier Niki Sharma, who represented Premier David Eby at the Saskatchewan meeting. Asked point blank if the New Democrats would be 'OK with fast-tracking' a pipeline to transport Alberta bitumen to Prince Rupert or Kitimat, Sharma replied: 'Well, you know what, at this stage, you've heard the premier say — we have a difference of opinion about whether or not a bitumen pipeline should go in … the northern part of the province.' Besides, said Sharma: 'There's no (pipeline) proponent at this time, there's no project that is really there to look at. Let's focus on those projects that are ready, with strong investment and alignment.' She's right that there is no current proposal for such a pipeline. One may be forthcoming after Carney's meeting with industry executives and Smith's lobbying on carbon capture projects in Alberta. In a followup statement, Sharma added: 'We are focusing on these shovel-ready projects, not theoretical projects with no proponents. There is also an existing, underused pipeline that Canadian taxpayers paid $34 billion for, with capacity to spare. She meant the Trans Mountain Pipeline expansion or TMX, which the New Democrats vowed to fight 'with every tool in the tool box' and failed to stop. Eby also made a disparaging reference to TMX at the recent conference of Western premiers. 'That pipeline is not at full capacity right now,' said Eby. 'Why wouldn't we ensure that that public infrastructure was fully used first before dividing ourselves on a project where there is no proponent.' Eby and Sharma exaggerate the degree to which the TMX is 'underused … with capacity to spare' after one year of operation. The Canadian Energy Regulator reports that the line has operated at about 80 per cent of its 890,000 barrel-per-day capacity since coming online in May 2024. Moreover, the performance improved in the first quarter of this year. 'The pipeline ran at about 85 per cent capacity during the three-month period ending in March,' Chris Varcoe reported in the Calgary Herald this week. The Globe and Mail's Emma Garney further reported that the line 'hit a high of 90 per cent' in March. The demand is such that Trans Mountain has already begun test work to boost capacity by up to 10 per cent by the end of 2026. A longer-term project would add pumping stations to boost it to 1.14 million barrels a day, later in the decade. So much for the B.C. NDP notion that the $34 billion pipeline is languishing through insufficient use. But rather than consult the country's energy regulator or the national newspapers, perhaps Eby and Sharma were taking their lead from Steven Guilbeault. Guilbeault served as environment minister in the Justin Trudeau Liberal government, where he flourished as a fan of carbon taxation and an opponent of fossil fuel expansion. Carney reassigned him to the Canadian Heritage Department at about the same time as the PM reduced the carbon tax to zero and began talking up the need to expand resource production. It didn't stop the new heritage minister from wandering outside his lane last month to announce that Canada has no need of more pipelines because TMX was operating at '40 per cent capacity' and the world was approaching 'peak oil production.' In the first instance, Guilbeault clearly didn't know what he was talking about and in the second, there's much room to debate about when peak oil will be reached. Still, there is a capacity issue regarding the TMX terminal in Burnaby, though not one that involves the pipeline. The terminal is already busy with tankers, having loaded some 741 in the first quarter of the year at a rate that fell just short of one a day in March. But tankers are unable to load fully because of the risk of grounding in Burrard Inlet. The New Democrats have recognized the limitation and come out in support of a federal proposal to dredge Burrard Inlet to a depth that full tankers can traverse. Leading the call is Energy Minister Adrian Dix. As NDP leader, Dix's snap decision to oppose TMX in the midst of the 2013 election campaign contributed to his loss to Christy Clark. Now that the line is running, Dix supports maximizing its use. 'We built it. We paid for it. We should use it,' he says, taking a realistic view of a project that cost him much. vpalmer@
Cision Canada
an hour ago
- Cision Canada
BioVaxys Issues Corporate Update
VANCOUVER, BC, June 3, 2025 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to provide a summary of current operating initiatives including the integration and disposition of assets acquired in February 2024 from the former IMV, Inc., the non-exclusive out-licensing of DPX to human and animal health companies, restarting clinical studies---notably DPX-surMAGE in advanced bladder cancer, expansion of the BioVaxys pipeline a through new formulations based on the DPX™ immune educating platforms, progress from our licensees, and most recently, the mitigation of risk through the significant reduction of a performance milestone provision in the Asset Purchase Agreement (APA) with Horizon Technology Finance Corp., and the engagement of D12 Capital Markets Inc. and its affiliate, Foundation Markets Inc., to act as agents in connection with a brokered private placement of minimum gross proceeds of $2,000,000 and maximum gross proceeds of up to $3,000,000. Over the next year, the Company's focus is on driving organic pipeline growth by: Expanding its early-stage pipeline by pursuing multiple out licensing opportunities and research collaborations where the Company's DPX platform can address specific needs (such as for a prophylactic food allergy vaccine and the collaboration with Sona Nanotech to develop novel cancer therapies), or antigen delivery limitations faced by LNPs (e.g. mRNA vaccines and neoantigen delivery); Reducing internal risk & the considerable funding requirements of late-stage clinical studies by out-licensing maveropepimut-S (MVP-S) for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma and Ovarian Cancer, seeking a co-development partner for DPX-RSV, and pursuing non-dilutive funding for further advancement of the DPX-FLU (influenza) and DPX-anthrax vaccines. Re-engagement of investigators at CHU de Québec-Université Laval and La Fondation du CHU de Québec, for a restart of the phase 1 study of DPX-surMAGE in advanced bladder cancer. BioVaxys stands at the forefront of innovation with its mission to develop advanced treatments in oncology, infectious disease, antigen desensitization, allergy, autoimmune diseases, and other immune dysfunction based on its DPX antigen delivery and immune-educating technology platform. The DPX platform has been proven safe, well tolerated, and effective in multiple preclinical, phase 1, and phase 2b clinical studies. Through a differentiated mechanism of action, the DPX platform is a major innovation in vaccine development that is a solution for the limitations faced by vaccines using other antigen delivery methods. The DPX platform provides a new and singularly unique way to deliver active ingredients to the immune system using a novel mechanism of action that does not release active ingredients at the site of the injection, but rather forces an active uptake of immune cells and delivery into the lymphatic nodes. The programming of immune cells happens in vivo and offers a more efficient approach that mimics the natural function of the immune system. The Company's late-stage clinical stage pipeline includes MVP-S in phase 2b clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers, and an innate immune activator and a universal CD4 T-cell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific, anti-tumor immune response. Results from a phase 1b/2 study of MVP-S in combination with low-dose cyclophosphamide in patients with recurrent ovarian cancer showed that this combination was well-tolerated and generated an overall response rate of 21% and a disease control rate of 63%. Notably, the response was observed in both platinum-resistant and platinum-sensitive patients. MVP-S, plus the immunotherapy drug Keytruda™ (pembrolizumab), also showed promising results in the treatment of patients with relapsed/refractory DLBCL, according to findings from a phase 2b study. The study analyzed MVP-S plus Keytruda and cyclophosphamide---including eight patients with relapsed/refractory DLBCL---whose functioning has been minimally affected, if at all, by their disease. Three of the six patients in the study arm experienced confirmed complete responses, meaning that there was no trace of their cancer left after treatment (2/8 of the patients had progressive disease). Kenneth Kovan, BioVaxys President & Chief Operating Officer, stated "The clinical data from MVP-S is very compelling and we think the vaccine can become a valuable tool in cancer immunotherapy. The significant investment for internal development of a later-stage program is such that it makes more sense for remaining clinical studies with MVP-S to be pursued by a company with the appropriate resources. Without going into detail, we are in early discussions with prospective licensors to achieve this objective." The Company also has data from phase 1 studies with DPX+surMAGE, a dual-targeted immunotherapy combining antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously. Survivin and MAGE-A9 are well characterized tumor-associated antigens frequently overexpressed in bladder tumors. Kovan further stated "We are working with the Principal Investigators at Laval University that conducted the foundational research on the surMAGE antigen combination to continue the previous phase 1 bladder cancer study. Our goal together with the investigators is to see this study funded and started in the upcoming months." The current DPX-surMAGE data has been submitted for presentation later this year at a major cancer conference. BioVaxys is seeking a partner for further clinical development of its DPX-RSV for Respiratory Syncytial Virus, which successfully completed a phase 1 human study for safety and efficacy. DPX-RSV demonstrated antigen-specific immune responses in 93% of subjects, with100% of responders in a 25μg single-dose cohort maintaining antigen-specific immunity one year post vaccination. Currently available RSV vaccines including GSK's Arexvy, Moderna's mResvia, and Pfizer's Abrysvo target either the F or G proteins of the virus and provide protection by neutralizing the RSV virus. Clinical measures of efficacy focus on the amount of neutralizing antibodies in the bloodstream. DPX-RSV works differently, as it targets the SH viral ectodomain of the RSV virus and, instead of neutralizing the virus, it enables the immune system to recognize and destroy RSV-infected cells. Completed BioVaxys preclinical proof of concept studies include DPX-rHA/DPX-FLU, an influenza vaccine candidate of recombinant hemagglutinin (whole protein ~300 amino acids) / whole heat killed virus package in DPX, and DPX-rPA, an and an anthrax vaccine consisting of DPX+ recombinant anthrax protective antigen. Animal challenge studies performed with lethal anthrax respiratory exposure levels with our DPX-based anthrax vaccine demonstrated 100% immunity following a single injection compared to current vaccines which require more than one dose. Kovan stated "We are looking for the right non-dilutive opportunities to further advance the clinical development of DPX-rHA/DPX-FLU with an even broader range of antigens. With DPX-rPA, we think it possible that with the excellent preclinical data, together with the clinical experience with DPX, might be sufficient to pursue registration " Pipeline Expansion Current research collaborations to expand the Company pipeline include a collaboration with AP Visionaries, Inc. of Ontario ("APVI") to jointly develop a proprietary DPX formulation to address the urgent need for a therapy to treat or alleviate the potentially life-threatening risk of certain food allergies, namely those triggered by exposure to peanut/tree nuts or eggs. Animal studies are slated to begin later this year when DPX-peanut antigen formulation is complete at The Schroeder Allergy and Immunology Research Institute of McMaster University in Ontario, an institute that consolidates clinicians, scientists, and data specialists in a one-stop shop to research the causes of life-threatening allergies and develop new treatments. Under the terms of the Collaboration, BioVaxys will provide funding for the preclinical study to evaluate in animal models the robustness of DPX antigen delivery and evaluate whether DPX transforms the underlying immunopathology of food allergy. APVI will oversee the preclinical program, with BioVaxys retaining all intellectual property rights to any resulting product. APVI will receive a royalty from BioVaxys on any gross sales from a resulting product, in addition to a milestone payment at first regulatory approval. On May 7, 2025, the Company and Sona Nanotech Inc. ("Sona") jointly announced that they entered into a research agreement to collaborate on the development of new cancer therapeutics based on the Company's DPX Immune Educating Platform in combination with Sona's Targeted Hyperthermia Therapy™, a photothermal cancer therapy that uses highly targeted infrared light and intra-tumoral gold nanorods to treat solid tumors. The collaboration will evaluate the immune stimulatory properties of DPX (without an antigen cargo) administered together with THT, as a characteristic of DPX is that it helps prime the innate immune system which in turn can activate and strengthen the adaptive immune response. The collaboration will also evaluate the combination use of THT together with a DPX formulation as a carrier for novel neoantigens expressed on the surface of tumor cells following immunotherapy, such as with THT. Neoantigens are unique proteins that are not present in healthy tissues that arise from changes in cancer cells and play a crucial role in stimulating anti-tumor immune response. Immunotherapy such as THT can trigger these tumor cell changes and the expression of neoantigens, so packaging a tumor neoantigen in DPX for presentation to the immune system is anticipated to accelerate THT's efficacy. The research studies based on the BioVaxys and Sona technologies will be conducted at Dalhousie University, Halifax, Nova Scotia, under the direction of Sona's CMO, Carman Giacomantonio, MD MSc FRCSC, Division of General and Gastrointestinal Surgery, Department of Pathology, Dalhousie University, and Barry Kennedy, PhD, of the Giacomantonio Immuno-Oncology Research Group at Dalhousie University. Other collaborations and licensing discussions are being finalized for expanding DPX formulations in the treatment of Zika virus. Licensing The Company has revenue generating licenses with Zoetis Inc. and SpayVac-for-Wildlife, Inc. for vaccines in the animal health field based on the Company's lipid encapsulation technology, with both licensors making excellent progress towards commercialization. SpayVac anticipates regulatory approval for a pZP immunocontraceptive vaccine for feral horses in the US, with supplemental regulatory submissions planned for the EU and Australia. Ongoing research with other antigens is targeting commercial aquaculture, companion animals, and other applications. On April 22, 2025, the Company announced the expansion of the Fields of Use in the current License Agreement with SpayVac to include commercial aquaculture, plus the farm-raised fish market, which will further increase BioVaxys' royalty revenue. Zoetis is preparing for regulatory submission for a pZP immunocontraception vaccine based on the Company's lipid encapsulation technology for cattle in Australia and Brazil. In a significant step to minimize risk, BioVaxys and Horizon Technology Finance Corporation ("Horizon") executed last month a follow-on Amendment ("Amendment") to the Asset Purchase Agreement dated February 11th, 2024 ("APA") for BioVaxys to acquire the entire portfolio of assets and intellectual property based on the DPX immune educating platform technology developed by Canadian biotechnology company, IMV Inc. The May 2025 Amendment lowers a performance milestone provision in the original APA for BioVaxys to demonstrate an aggregate capital raise of USD $10M, so that the new net performance milestone required to be raised in any form (including, but not limited to equity, grants, licensing fees, or loans) is now significantly lowered to USD $2,028,636. If BioVaxys is successful in meeting this milestone by September 30, 2025, the milestone requirement shall end and be of no further force or effect. To help support its objectives, on May 22, 2025, the Company announced a proposed consolidation of the common shares of the Company on the basis of ten (10) pre-consolidation Common Shares for one (1) post-consolidation Common Share. As at May 22, 2025, the Company has 293,425,203 Common Shares issued and outstanding. James Passin, CEO of BioVaxys, stated "The share consolidation is a necessary step to attract the institutional capital necessary for business development as well as to tighten up the float to increase the likelihood of sustained share appreciation on future catalysts." Immediately following the Consolidation and excluding the Common Shares to be issued in connection with this Offering, will have approximately 29,342,520 Common Shares issued and outstanding, prior to rounding of fractional Common Shares. About BioVaxys Technology Corp. BioVaxys Technology Corp. ( is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on its DPX™ immune-educating technology platform and its HapTenix© 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization for food allergy, and other immunological diseases. Through a differentiated and unique mechanism of action, the DPX platform delivers instruction to the immune system to generate a specific, robust, and persistent immune response. The Company's clinical stage pipeline includes maveropepimut-S (MVP-S), based on the DPX platform, in phase 2b clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers, and also delivers an innate immune activator and a universal CD4 T cell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific anti-tumor immune response. BioVaxys is also developing DPX+surMAGE, a dual-targeted immunotherapy combining antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously, DPX-RSV for Respiratory Syncytial Virus, and DPX+rPA for peanut allergy prophylaxis, as well as several viral vaccines. BioVaxys has licensed its patented liposome-based delivery platform to Zoetis, Inc. and SpayVac-for-Wildlife, Inc. for selected animal health applications. BioVaxys common shares are listed on the CSE under the stock symbol 'BIOV', trade on the Frankfurt Bourse (FRA: 5LB), and in the US (OTCQB: BVAXF). For more information, visit and connect with us on X and LinkedIn. ON BEHALF OF THE BOARD Signed "James Passin" James Passin, Chief Executive Officer Phone: +1 740 358 0555 Cautionary Statements Regarding Forward Looking Information This press release includes certain "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements") within the meaning of applicable Canadian and United States securities legislation including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein, without limitation, statements relating the future operating or financial performance of the Company, are forward looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or "should" occur or be achieved. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements. These forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that BioVaxys' vaccines will not prove to be effective and/ or will not receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval, and, if so, whether its vaccine products will be commercially accepted and profitable, the expenses, delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses, financial and development obligations under license arrangements in order to protect its rights to its products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties. The Company does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
